aspirin

ARRIVE: la aspirina en el ojo de la tormenta de la prevención primaria

ESC 2018 | ARRIVE: Aspirin in the Eye of the Storm of Primary Prevention

Aspirin failed to reach the primary endpoint in a population that was at risk of experiencing cardiovascular disease. However, something that a short time ago seemed obvious could not be proved by randomizing 12,000 patients. The ARRIVE trial, presented at the European Society of Cardiology (ESC) Congress 2018 and simultaneously published in The Lancet, joins the<a href="https://solaci.org/en/2018/08/29/esc-2018-arrive-aspirin-in-the-eye-of-the-storm-of-primary-prevention/" title="Read more" >...</a>

ASCEND: Aspirina para prevención primaria en diabéticos no pasa el costo/beneficio

ESC 2018 | ASCEND: Aspirin for Primary Prevention in Diabetic Patients Fails the Cost-Benefit Analysis

The obvious risk of bleeding posed by aspirin was too clear in this work, casting a shadow of doubt over the indication of aspirin for primary prevention in diabetic patients. According to the ASCEND trial, presented at the European Society of Cardiology (ESC) 2018 Congress and simultaneously published in NEJM, aspirin reduces cardiovascular events as<a href="https://solaci.org/en/2018/08/28/esc-2018-ascend-aspirin-for-primary-prevention-in-diabetic-patients-fails-the-cost-benefit-analysis/" title="Read more" >...</a>

ticagrelor vs. aspirina

Can We Prevent Cardiovascular Events without Aspirin?

As regards the use of antithrombotic agents, the risk of bleeding will always be an issue, and in the case of aspirin this risk is twice as big: it does have the desired antiaggregation effect, but on top of the increased bleeding risk, it has a damaging effect on stomach lining that increases the risk<a href="https://solaci.org/en/2018/07/25/can-we-prevent-cardiovascular-events-without-aspirin/" title="Read more" >...</a>

THEMIS: eventos isquémicos y hemorrágicos en difícil equilibrio para el ticagrelor crónico

New Study Shows Ticagrelor + Aspirin Reduce Events Rate

Just when we were starting to understand how long dual antiplatelet therapy should be for our patients,&nbsp;JACC&nbsp;publishes this study where ticagrelor&nbsp;combined with aspirin significantly reduces relative and absolute events rate at long term, especially in patients with multivessel disease. The PEGASUS-TIMI 54 assessed the long-term benefits of two different doses of ticagrelor (60 mg or<a href="https://solaci.org/en/2018/03/21/new-study-shows-ticagrelor-aspirin-reduce-events-rate/" title="Read more" >...</a>

AAS durante cirugías no cardíacas: solamente en pacientes con angioplastia previa

Aspirin During Noncardiac Surgery: Only in Patients with Prior Angioplasty

A new analysis from the POISE-2 study suggests that aspirin should not be withheld prior to noncardiac surgery in patients with a history of coronary angioplasty, even if their coronary procedure occurred several years earlier. Patients with a history of coronary angioplasty who need cardiac surgery are more likely to benefit from continued aspirin therapy,<a href="https://solaci.org/en/2018/01/02/aspirin-during-noncardiac-surgery-only-in-patients-with-prior-angioplasty/" title="Read more" >...</a>

DACAB: Ticagrelor and Aspirin Improve Vein Graft Patency

According to this Chinese study,&nbsp;dual antiplatelet therapy&nbsp;with&nbsp;ticagrelor&nbsp;and&nbsp;aspirin&nbsp;improves vein graft patency a year after surgery without increasing the risk for major bleeding. &nbsp; Treatment with the P2Y12 inhibitor ticagrelor in combination with aspirin has been widely accepted for patients with acute coronary syndrome undergoing angioplasty. However, there were no related data regarding surgical revascularization. Read also:&nbsp;&#8220;Ticagrelor<a href="https://solaci.org/en/2017/11/16/dacab-ticagrelor-and-aspirin-improve-vein-graft-patency-2/" title="Read more" >...</a>

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

The End of Aspirin for Anticoagulated Patients Undergoing PCI

The discussion about the best anti-thrombotic strategy for patients with&nbsp;atrial fibrillation&nbsp;undergoing PCI seemed never-ending until the RE-DUAL PCI trial was published in the New England Journal of Medicine (NEJM). This study has arrived to simplify the tough choice between the risk of a thrombotic event vs. the risk of bleeding with a simpler scheme, without<a href="https://solaci.org/en/2017/11/08/the-end-of-aspirin-for-anticoagulated-patients-undergoing-pci/" title="Read more" >...</a>

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

ARTE: Aspirin or Aspirin and Clopidogrel after TAVR?

Courtesy of SBHCI. This study presented at Euro PCR and simultaneously published by JACC Cardiovascular Interventions poses a question that has remained unanswered since the start of TAVR. &nbsp; There is little information on the optimal antithrombotic therapy after transcatheter aortic valve replacement (TAVR). In general, patients receive between 1 and 6 months of dual<a href="https://solaci.org/en/2017/05/25/arte-aspirin-or-aspirin-and-clopidogrel-after-tavr/" title="Read more" >...</a>

desensibilizacion a la aspirina

Aspirin Desensitization in Patients with Coronary Artery Disease

There are limited data on aspirin desensitization in patients with coronary artery disease (CAD). The aim of this study was to test the safety and efficacy of a rapid desensitization protocol inpatients with a history of aspirin sensitivity about to receive PCI. &nbsp; This was a prospective multicenter observational study, carried out in seven Italian<a href="https://solaci.org/en/2017/03/06/aspirin-desensitization-in-patients-with-coronary-artery-disease/" title="Read more" >...</a>

ticagrelor vs. aspirina

Ticagrelor: Similar to Aspirin in Patients with Stroke or TIA

Ticagrelor might be a more effective antiplatelet therapy than aspirin for the prevention of recurrent stroke and cardiovascular events in patients admitted for acute cerebral ischemia. &nbsp; This double-blind, controlled trial randomized 13,199 patients from 33 countries. Subjects presented a non-severe stroke or a high-risk transient ischemic attack (TIA) (not considered as cardioembolic) and had not received<a href="https://solaci.org/en/2016/08/24/ticagrelor-similar-to-aspirin-in-patients-with-stroke-or-tia/" title="Read more" >...</a>

Top